Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 3/20 | 0.35 |
| ▸ | CCND1 | P24385 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102699 | 0.96 | TNF (0.45) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL1102595 | 0.93 | TNF (0.47) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL1102786 | 0.88 | CYP11B1 (0.40) | TNFCYP1A2KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12887402 | 0.87 | TNF (0.36) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL12886983 | 0.87 | MAPT (0.39) | TNFKDM4EPOLB | |
| SCHEMBL1102907 | 0.83 | TNF (0.54) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL1102905 | 0.83 | TNF (0.47) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL1102491 | 0.82 | CRHBP (0.43) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL1103691 | 0.82 | TNF (0.56) | TNFCYP1A2KDM4ELMNACYP3A4 | |
| SCHEMBL1102541 | 0.82 | TNF (0.56) | TNFCYP1A2KDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | TNF 3803/4885CYP1A2 1437/4885KDM4E 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.